Could Active Hexose Correlated Compound (AHCC) Currently Be an Appropriate Choice to Clear Human Papillomavirus Infection?

Maryam Farasatinasab, Nassiri S, Setare Nassiri
Journal of clinical pharmacology · 2022 · vol. 62(12) , pp. 1576–1577 · doi:10.1002/jcph.2118 · PMID:35775905
other OA: bronze public-domain-us
🔓 Open OA copy View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This paper investigates whether Active Hexose Correlated Compound (AHCC) can effectively clear human papillomavirus (HPV) infections.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections Papillomavirus Infections

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-13T09:25:22.628771+00:00
pubmed
last seen: 2026-07-14T06:08:25.154024+00:00
unpaywall
last seen: 2026-05-15T02:00:00.661756+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine